OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.
|Original language||English (US)|
|Journal||Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery|
|Issue number||1 Suppl|
|State||Published - Mar 2013|
ASJC Scopus subject areas